There is an urgent need for an effective, science-backed approach that significantly improves the odds of individuals beating addiction and improving patient care, so we can help address the global cost of addiction for individuals, families and society at large. Entheon is committed to creating impact where other options have failed, even against treatment-resistant forms of addiction, through early intervention and a scientifically sound solution
We are researching and developing psychedelic treatments using the DMT molecule as a benchmark upon which to improve drug safety and scalability. In addition, we are leveraging DMT to develop a personalized medicine platform that uses an individual’s genetics – or biological fingerprint – alongside EEG data, to deliver an in-clinic treatment program that’s optimized to each patient's needs.
Development of drugs, using DMT as the pharmacological benchmark
Identification, analysis and predictive use of genetics and EEG biomarkers in the selection and management of drug treatment
Development of treatment algorithms through the analysis of patient data.
A wholly-owned subsidiary of Entheon, HaluGen Life Sciences is a biotech company that has developed a pre-screening test to identify genetic markers predictive of an individual’s reaction to hallucinogenic drugs, the “Psychedelics Genetic Test.
Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications, including psilocybin, MDMA, DMT, LSD, 2C-B, and mescaline.
The Centre for Human Drug Research (CHDR) is an independent institute that specializes in cutting-edge early-stage clinical drug research. Combining innovative methods and technologies, state-of-the-art facilities, and talented, motivated researchers helps CHDR maximize their clients’ success. In addition, CHDR places the highest priority on their subjects’ comfort and safety, and they play an active role in helping educate the medical and clinical research communities. In addition, CHDR utilizes the services of the GMP-compliant the Leiden University Medical Center (LUMC). The LUMC pharmacy prepares and delivers the pharmaceutical products, including investigational medicinal products, and offers tailor-made solutions to help answer our sponsors’ questions.
Based out of Ness Ziona, Israel, Science in Action (SIA) is a preclinical contract research organization (CRO) founded in 2010 by immunologist Raanan Margalit. SIA is GLP-accredited for toxicology studies in multiple areas, with extensive experience in tailor-made preclinical research in in-vivo and in-vitro models.
Founded in Austin, Texas, Heading Health provides a full-suite of therapies and diagnostic tools, including Spravato® (esketamine) nasal spray and Intramuscular (IM) ketamine designed to target depression, anxiety, PTSD and OCD indications. The Heading Health management team is experienced in operating and scaling psychiatric clinics across multiple states, securing insurance coverage and pioneering the most efficient and effective breakthroughs in clinical research and technologies.
A Toronto-based company focused on the research and development of a data-driven, cloud-based neuro platform based on EEG-analysis and machine learning to improve mental health for all. Divergence’s platform and research enhance clinical and personal mental health assessments by supplementing self-reporting methods with an easy-to-understand, cloud-based EEG software platform, offering individualized neurofeedback protocols driven by machine learning and AI combined with therapist interaction.
For over 40 years the Ofichem Group has been working to improve health for humans and animals by providing high quality Active Pharmaceutical Ingredients. API’s that not only meet client’s needs but also comply with stringent health and safety regulations.